目的 评价养正消积胶囊联合盐酸厄洛替尼片治疗晚期非小细胞肺癌的临床疗效。方法 选取2015年12月-2017年12月宝鸡市中心医院治疗的90例表皮生长因子受体基因突变阳性的非小细胞肺癌患者作为研究对象，随机将患者分为对照组和治疗组，每组各45例。对照组口服盐酸厄洛替尼片，150 mg/d；治疗组在对照组基础上口服养正消积胶囊，4粒/次，3次/d。两组患者均治疗8周。观察两组患者的临床疗效，同时比较两组的生存情况、肿瘤标志物和不良反应。结果 治疗后，对照组和治疗组总缓解率分别为22.22%、24.44%，疾病控制率分别为60.00%、66.67%，两组比较差异无统计学意义。治疗后，两组患者肿瘤无进展生存期（PFS）和总生存期（OS）无显著差异。治疗后，两组糖类抗原19-9（CA19-9）、细胞角蛋-19片段（CYFRA21-1）、癌胚抗原（CEA）水平均显著降低，同组治疗前后比较差异具有统计学意义（P<0.05）。且治疗组肿瘤标志物水平明显低于对照组，两组比较差异具有统计学意义（P<0.05）。治疗后，治疗组恶心呕吐、皮疹、转氨酶升高例数显著少于对照组，两组比较差异具有统计学意义（P<0.05）。结论 养正消积胶囊联合盐酸厄洛替尼片治疗晚期非小细胞肺癌具有较好的临床疗效，可有效降低肿瘤标志物水平，减轻不良反应，具有一定的临床推广应用价值。

Objective To evaluate the clinical efficacy of Yangzheng Xiaoji Capsules combined with Erlotinib Hydrochloride Tablets in treatment of advanced non-small cell lung cancer. Methods Patients (90 cases) with advanced non-small cell lung cancer with positive epidermal growth factor receptor gene mutation in Baoji Central Hospital from December 2015 to December 2017 were randomly divided into control and treatment groups, and each group had 45 cases. Patients in the control group were po administered with Erlotinib Hydrochloride Tablets, 150 mg/d. Patients in the treatment group were po administered with Yangzheng Xiaoji Capsules on the basis of the control group, 4 grains/time, three times daily. Patients in two groups were treated for 8 weeks. After treatment, the clinical efficacies were evaluated, and survival situation, tumor markers, and the adverse reactions in two groups were compared. Results After treatment, overall remission rates in the control and treatment groups were 22.22% and 24.44% respectively, disease control rates in the control and treatment groups were 60.00% and 66.67%, respectively, but there were not statistically significant difference between two groups. After treatment, there was no significant difference in PFS and OS between two groups. After treatment, the levels of CA19-9, CYFRA21-1, and CEA in two groups were significantly decreased, and the difference was statistically significant in the same group (P<0.05). And the tumor markers levels in the treatment group were significantly lower than those in the control group, with significant difference between two groups (P<0.05). After treatment, the numbers of nausea and vomiting, rash, and transaminase elevation in the treatment group was significantly lower than those in the control group, and there were differences between two groups (P<0.05). Conclusion Yangzheng Xiaoji Capsules combined with Erlotinib Hydrochloride Tablets has clinical curative effect in treatment of advanced non-small cell lung cancer, can effectively decrease the tumor markers levels, reduce the adverse reactions, which has a certain clinical application value.